DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company is
pleased to announce Elsevier Business Intelligence has named clinical drug DM199
as one of the Top Cardiovascular/Metabolic Projects to Watch.


The Top 10 list is selected by an independent panel each year to highlight
compounds that address a large, unmet market, strong science and a diversity of
indications. Other criteria include the potential for new opportunities beyond
initial indications, multi-level partnering opportunities and a strong company
behind the compound. 


Companies selected in the Top Cardiovascular/Metabolic Projects to Watch were
screened against strict criteria and are considered the most attractive
cardiovascular/metabolic opportunities in the industry. Past Top 10 candidates
have signed $US17 billion in potential acquisitions and alliances including
Vectura, AVEO, Trophos, BiPar, Myogen, Sirtris and Kosan.


DiaMedica will present the latest research on DM199 at the Therapeutic Area
Partnerships meeting on November 19, 2013 at the Hyatt regency in Boston, MA.


"We are very pleased to have DM199 recognized as one of the most promising
treatments under development and look forward to presenting our research to the
pharmaceutical community," said Rick Pauls, DiaMedica's President and CEO. 


DM199 is currently in a randomized, double-blinded, placebo-controlled Phase
I/II clinical study in Type 2 diabetic patients and healthy volunteers. Results
to date demonstrate DM199 has achieved its primary clinical endpoints of safety,
tolerability and sustained pharmacokinetic (PK) properties in healthy volunteers
and diabetic patients. In addition, results from secondary endpoints in Type 2
diabetic patients assessing glucose control were consistent with an insulin
sensitization mechanism of action. 


About DiaMedica 

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024